JP2022078268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022078268A5 JP2022078268A5 JP2022038221A JP2022038221A JP2022078268A5 JP 2022078268 A5 JP2022078268 A5 JP 2022078268A5 JP 2022038221 A JP2022038221 A JP 2022038221A JP 2022038221 A JP2022038221 A JP 2022038221A JP 2022078268 A5 JP2022078268 A5 JP 2022078268A5
- Authority
- JP
- Japan
- Prior art keywords
- powder composition
- pharmaceutical powder
- intranasal pharmaceutical
- composition according
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000000843 powder Substances 0.000 claims 25
- 239000013543 active substance Substances 0.000 claims 15
- 239000002245 particle Substances 0.000 claims 13
- 239000002562 thickening agent Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 150000005846 sugar alcohols Chemical class 0.000 claims 7
- 229920002678 cellulose Polymers 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 239000011149 active material Substances 0.000 claims 4
- 229960004704 dihydroergotamine Drugs 0.000 claims 4
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- -1 carbopole Polymers 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 235000010449 maltitol Nutrition 0.000 claims 2
- 239000000845 maltitol Substances 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 229940035436 maltitol Drugs 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 claims 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical group CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371298P | 2016-08-05 | 2016-08-05 | |
| US62/371,298 | 2016-08-05 | ||
| PCT/IB2017/001121 WO2018025089A2 (en) | 2016-08-05 | 2017-08-04 | Pharmaceutical compositions |
| JP2019506145A JP2019527703A (ja) | 2016-08-05 | 2017-08-04 | 鼻腔内薬学的粉末組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506145A Division JP2019527703A (ja) | 2016-08-05 | 2017-08-04 | 鼻腔内薬学的粉末組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022078268A JP2022078268A (ja) | 2022-05-24 |
| JP2022078268A5 true JP2022078268A5 (cg-RX-API-DMAC7.html) | 2022-07-08 |
| JP7366178B2 JP7366178B2 (ja) | 2023-10-20 |
Family
ID=60084012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506145A Pending JP2019527703A (ja) | 2016-08-05 | 2017-08-04 | 鼻腔内薬学的粉末組成物 |
| JP2022038221A Active JP7366178B2 (ja) | 2016-08-05 | 2022-03-11 | 鼻腔内薬学的粉末組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506145A Pending JP2019527703A (ja) | 2016-08-05 | 2017-08-04 | 鼻腔内薬学的粉末組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10792253B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3493789A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2019527703A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102489453B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109640947A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017307306B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3030359A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019001313A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018025089A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049059B1 (en) | 2013-09-24 | 2021-11-03 | Satsuma Pharmaceuticals, Inc. | Intranasal dhe formulation for the treatment of headache |
| US20200297734A1 (en) | 2015-06-19 | 2020-09-24 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| US20190142841A1 (en) * | 2015-06-19 | 2019-05-16 | Harrow Health, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| EP3341059B1 (en) | 2015-09-10 | 2022-03-02 | Impel NeuroPharma Inc. | In-line nasal delivery device |
| CA3030359A1 (en) * | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| BR112020013744A8 (pt) | 2018-01-05 | 2022-10-18 | Impel Neuropharma Inc | Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão |
| CA3122396A1 (en) | 2018-12-11 | 2020-06-18 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
| CN111346078B (zh) * | 2018-12-21 | 2022-06-10 | 宜昌人福药业有限责任公司 | 一种他喷他多或其药学上可接受的盐经鼻粘膜给药的药物组合物及其制备方法和应用 |
| JP7900916B2 (ja) * | 2019-05-16 | 2026-08-05 | 株式会社新日本科学 | 経鼻投与用の粉末製剤及びその製造方法 |
| CN114269712A (zh) * | 2019-05-28 | 2022-04-01 | 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 | 制备核糖醇的组合物和方法 |
| CA3166250A1 (en) | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| EP4121083A4 (en) * | 2020-03-18 | 2023-11-29 | Cara Therapeutics, Inc. | OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS |
| CN121265577A (zh) | 2020-05-18 | 2026-01-06 | 奥瑞克索股份公司 | 用于药物递送的药物组合物 |
| KR102563646B1 (ko) * | 2021-04-06 | 2023-08-07 | (주)메디코어 | 비강 세정용 분말 조성물의 제조방법 및 그에 따라 제조된 비강 세정용 분말 조성물 |
| WO2022224030A1 (en) * | 2021-04-20 | 2022-10-27 | Sava Healthcare Ltd | Dry powder inhalation (dpi) formulation |
| TW202333658A (zh) | 2021-11-25 | 2023-09-01 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素之新穎醫藥組合物 |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20260232581A1 (en) * | 2022-09-28 | 2026-08-13 | Board Of Regents, The University Of Texas System | Respiratory dry powder delivery |
| CN115737568A (zh) * | 2022-11-24 | 2023-03-07 | 东南大学 | 一种利培酮鼻用粉雾剂及其制备方法 |
| EP4626438A2 (en) * | 2022-12-01 | 2025-10-08 | Pinata Holdings Inc. | Inhalable hormone receptor agonist formulations |
| CN117003689A (zh) * | 2023-09-28 | 2023-11-07 | 成都瑞尔医药科技有限公司 | 一种碘解磷定的晶型及其制备方法 |
| WO2025101272A1 (en) * | 2023-11-11 | 2025-05-15 | Css Pharma L.L.C. | Pharmaceutical composition for the acute treatment of migraine and other forms of headache |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169849A (en) * | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
| SE9604486D0 (sv) * | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
| CA2341732C (en) * | 1998-08-26 | 2008-08-19 | Teijin Limited | Powder composition for nasal administration |
| US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
| GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| CA2583794C (en) * | 2004-10-11 | 2015-05-26 | Nasaleze Ppm Limited | Compositions for intranasal administration |
| EP1829549A1 (en) * | 2004-12-17 | 2007-09-05 | Ono Pharmaceutical Co., Ltd. | Amorphous composition |
| ES2652415T3 (es) * | 2006-12-26 | 2018-02-02 | Shin Nippon Biomedical Laboratories, Ltd. | Preparación para aplicación transnasal |
| US20110077272A1 (en) | 2008-02-01 | 2011-03-31 | Vectura Limited | Pulmonary formulations of triptans |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
| KR20160148041A (ko) | 2009-04-24 | 2016-12-23 | 아이슈티카 피티와이 리미티드 | 캅셀화된 나노입자의 상업적 규모의 생산 |
| US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| US8827946B2 (en) | 2009-07-31 | 2014-09-09 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| ES2659761T3 (es) | 2011-01-31 | 2018-03-19 | Shin Nippon Biomedical Laboratories, Ltd. | Dispositivos de administración intranasal |
| EP2601973A1 (en) | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
| AU2014226192B2 (en) | 2013-03-04 | 2018-07-26 | Besins Healthcare Luxembourg Sarl | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles |
| EP3049059B1 (en) | 2013-09-24 | 2021-11-03 | Satsuma Pharmaceuticals, Inc. | Intranasal dhe formulation for the treatment of headache |
| RU2570092C2 (ru) | 2013-09-30 | 2015-12-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" | Способ выявления различий структурного состояния целлюлозы |
| CA3030359A1 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
-
2017
- 2017-08-04 CA CA3030359A patent/CA3030359A1/en active Pending
- 2017-08-04 WO PCT/IB2017/001121 patent/WO2018025089A2/en not_active Ceased
- 2017-08-04 AU AU2017307306A patent/AU2017307306B2/en active Active
- 2017-08-04 MX MX2019001313A patent/MX2019001313A/es unknown
- 2017-08-04 JP JP2019506145A patent/JP2019527703A/ja active Pending
- 2017-08-04 KR KR1020197005848A patent/KR102489453B1/ko active Active
- 2017-08-04 EP EP17784385.1A patent/EP3493789A2/en active Pending
- 2017-08-04 US US15/668,871 patent/US10792253B2/en active Active
- 2017-08-04 EP EP26188236.9A patent/EP4792885A2/en active Pending
- 2017-08-04 CN CN201780049097.7A patent/CN109640947A/zh active Pending
-
2020
- 2020-08-28 US US17/005,647 patent/US11872314B2/en active Active
-
2022
- 2022-03-11 JP JP2022038221A patent/JP7366178B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7366178B2 (ja) | 鼻腔内薬学的粉末組成物 | |
| JP5944514B2 (ja) | 固体分散体 | |
| JP4334869B2 (ja) | 溶解性または経口吸収性の改善された組成物 | |
| CA3037273C (en) | Orally administered corticosteroid compositions | |
| CN102946868B (zh) | 包含抗毒蕈碱药的干粉制剂 | |
| TWI540128B (zh) | 醫藥組合物 | |
| ES2285233T3 (es) | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. | |
| TWI522100B (zh) | 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途 | |
| JP5600747B2 (ja) | 口腔内分散性製剤 | |
| HUP0401670A2 (hu) | Montelukast-tartalmú granula készítmény | |
| TW200930712A (en) | The amorphous of a heterocyclic compound, the solid dispersoid consisting it, the preparation, and the process for preparing thereof | |
| JP2021120376A (ja) | Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物 | |
| JP4465152B2 (ja) | 味をマスキングした、顆粒及びコーティングされた顆粒剤 | |
| JP2008013480A (ja) | 薬物含有微粒子およびその製造方法 | |
| EP3134076A1 (en) | A stable montelukast solution | |
| JP2010535196A (ja) | 活性成分のコーティング膜が保護される口腔内崩壊剤形を製造するための組成物 | |
| TWI780270B (zh) | 固體分散體 | |
| JP5297194B2 (ja) | 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法 | |
| JP4413866B2 (ja) | ジアリールビニレン化合物の安定化方法 | |
| EP3505164A1 (en) | An effervescent composition comprising erdosteine | |
| JP4648491B2 (ja) | ジベンゾ［ｂ，ｅ］オキセピン誘導体を含有する固形製剤 | |
| WO2013077829A1 (en) | Water-soluble pharmaceutical granules | |
| JP2007502790A (ja) | Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用 | |
| WO2013100870A1 (en) | New antipsychotic compositions | |
| KR20070102065A (ko) | 바데나필의 경구용 속효제형 |